



I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Label No. EV971742076US, on the date shown below in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: July 13, 2007

Signature:

Christina Andrews
(Christina Andrews)

Docket No.: 47624CIP(71417)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Jeffrey M. Isner et al.

Application No.: 10/696,391

Confirmation No.: 6371

Filed: October 28, 2003

Art Unit: 1633

For: COMPOSITIONS AND METHODS FOR
MODULATING VASCULARIZATION

Examiner: Q. Nguyen

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

Copies of the references on the PTO/SB/08 are not provided.

Those documents which are marked with a double asterisk (**) next to the Cite No. in the attached form PTO/SB/08 are not supplied because they were previously cited by or submitted to the Office in prior application numbers 09/265,041,

620331

07/16/2007 RMEBRAHT 00000018 041105 10696391

02 FC:1806

180.00 DA

09/698,323 and 10/714,574 and relied upon in this application for an earlier filing date under 35 U.S.C. 120.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 04-1105 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 47624CIP(71417). A duplicate copy of this paper is enclosed.

Dated: July 13, 2007

Respectfully submitted,

By 

Melissa Hunter-Ensor, Ph.D.

Registration No.: 55,289

EDWARDS ANGELL PALMER &
DODGE LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 517-5580

Attorneys/Agents For Applicant



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/696,391-Conf. #6371
				Filing Date	October 28, 2003
				First Named Inventor	Jeffrey M. Isner
				Art Unit	1633
				Examiner Name	Q. Nguyen
Sheet	1	of	1	Attorney Docket Number	47624CIP(71417)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA**	US 4,296,100			
	AB**	US 5,219,739			
	AC**	US 5,229,496			
	AD**	US 5,332,671			
	AE**	US 5,652,225			
	AF**	US 6,133,231			
	AG**	US-5,612,211		Wilson et al.	
	AH**	US-5,646,043	07-08-1997	Emerson et al.	
	AI**	US-5,941,868		Kaplan et al.	
	AJ**	US-5,980,887	11-09-1999	Isner et al.	
	AK**	US-6,121,246		Isner	
	AL**	US-6,258,787-B1	07-10-2001	Isner	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA**	PCT/EP85/00326				
	BB**	PCT/US96/15813				
	BC**	WO95/22618				
	BD**	WO97/14307				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA**	Aharinejad et al. CSF-1 Treatment Promotes Angiogenesis In The Metaphysis Of Osteopetrotic (Toothless, tl) Rats. Bone 16:315-324, 1995.	
	CB**	Aiuti et al. The Chemokine SDF-1 is a Chemoattractant For Human CD34 + Hematopoietic Progenitor Cells and Provides a New Mechanism To Explain the Mobilization of CD34+ Progenitors to Peripheral Blood. J. Exp. Med. 185:111-120, 1997.	
	CC**	Asahara et al. VEGF Contributes to Postnatal Neovascularization by Mobilizing Bone Marrow-derived Endothelial Prognitor Cells. EMBO J. 18:3964-3972, 1999.	
	CD**	Asahara, et al., Blood, 67:842 (1986)	
	CE**	Baffour, et al., "Enhanced Angiogenesis and Growth of Collaterals by In Vivo Administration of Recombinant Basic Fibroblast Growth Factor in a Rabbit Model of Acute Lower Limb Ischemia: Dose-Response Effect Of Basic Fibroblast Growth Factor" J. Vasc. Surg., 16:181-	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	10/696,391-Conf. #6371	
			Filing Date	October 28, 2003	
			First Named Inventor	Jeffrey M. Isner	
			Art Unit	1633	
			Examiner Name	Q. Nguyen	
Sheet	2	of	1	Attorney Docket Number	47624CIP(71417)

		91 (1992).	
CF**		Baffour, et al., J. Vasc. Surg., 16:181-91 (1992)	
CG**		Bevilacqua, M. P., Annu. Rev. Immuno., 11:767 (1993)	
CH**		Brooks, P. C. et al., Science 264:569 (1994)	
CI**		Civin, C.I. et al., J. Immunol. 133:157 (1984)	
CJ**		D'Amore, P. A. et al., Annu. Rev. Physiol. 49:453 (1987)	
CK**		Dang et al., Clin. Canc. Resea. 5:471-474 (1999)	
CL**		Davis, et al., Hum Gene Ther., 4:151 (1993)	
CM**		DeVries, C. et al., Science 255:989 (1992)	
CN**		Felgner, P.L., et al., Nature 349:351-352 (1/24/91)	
CO**		Ferrara, et al., Biochem. Biophys. Res. Commun., 161:851-855 (1998)	
CP**		Ferrara, Trends Cardio. Med., 3:244-250 (1993)	
CQ**		Fina, J. et al., Blood 75: 2417 (1990)	
CR**		Flamme I. Et al., Development, 116:435 (1992)	
CS**		Folkman, J. et al., Science 235:442 (1987)	
CT**		Folkman, N. Engl. J. Med., 285:1182-1186 (1971)	
CU**		Giodano et al., Nature Medicine 2: No.5 534-539 (Examiner cited)	
CV**		Grant et al., Proc. Natl. Acad. Sci. 90:1937-1941 (1993) (Examiner cited)	
CW**		His, W., Abhandl., K. S. Ges. Wiss. Math. Phys. 22, 171 (1900)	
CX**		Houck, et al., Mol. Endocrinol., 8:1806-1814 (1991)	
CY**		Jaffe, E. A. et al., J. Clin. Invest. 52:2745 (1973)	
CZ**		Joukou, et al., J. of Cell. Phys., 173:211-215 (1997)	
CCA**		Katz, F. et al., Leuk. Res. 9: 191 (1985)	
CCB**		Kawakami et al., Brain Research Vol. 697:104-111 (1995) (Examiner cited)	
CCC**		Kessinger A., et al., Blood, 77:211 (1991)	
CCD**		Klagsbrun, et al., Annu. Rev. Physiol., 53:217-239 (1991)	
CCE**		Matthews, W. et al., "A Receptor Tyrosine Kinase cDNA Isolated from a Population of Enriched Primitive Hematopoietic Cells and Exhibiting Close Genetic Linkage to c-kit" Proc. Natl. Acad. Sci. USA, 88:9026-9030 (1991).	
CCF**		Miettinen, M. et al., Am. J. Clin. Pathol., 79:32 (1983)	
CCG**		Nabel et al., Nature, 362:844(1993)	
CCH**		Newman, P. J. et al., Science 247:1219 (1990)	
CCI**		Pepper, M. S. et al., Biochem. Biophys. Res. Comm., 181:902 (1991)	
CCJ**		Polterak, et al., J. Biol. Chem., 272:7151-7158 (1997)	
CCK**		Pu, et al., Circulation, 88:208-215 (1993)	
CCL**		Pu, et al., J. Surg. Res., 54:575-83 (1993)	
CCM**		Risau, W. et al., Development 102, 471 (1998)	
CCN**		Safi et al., J. Mol. Cell. Cerdiol. 29:2311-2325 (1997) (Examiner cited)	
CCO**		Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1989)	
CCP**		Sato, Y. et al., Exp. Cell Res. 204:223 (1993)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/696,391-Conf. #6371
				Filing Date	October 28, 2003
				First Named Inventor	Jeffrey M. Isner
				Art Unit	1633
				Examiner Name	Q. Nguyen
Sheet	3	of	1	Attorney Docket Number	47624CIP(71417)

	CCQ**	Schaper, W. et al., Circ. Res. 28, 671 (1971)	
	CCR**	Schnurch, H. et al., Development 119, 957 (1993)	
	CCS**	Sheridan, W. et al., Lancet 339:640 (1992)	
	CCT**	Shi et al., "Evidence fo Circulating Bone Marrow-Derived Endothelial Cells," Blood, 92:362-367 (1998).	
	CCU**	Shibuki, K. et al., Nature 358:676 (1991)	
	CCV**	Shpall, E.J. et al., J. Clin. Oncol, 12:28 (1994)	
	CCW**	Simmons, P. J. et al., Blood 80:388 (1992)	
	CCX**	Stratford-Perricaudet L.D., et al. J. Clin. Invest. 90:626-630 (1992)	
	CCY**	Symes et al., Current Opinion in Lipidology, 5:305-312 (1994)	
	CCCA**	Takeshita, et al., Circulation, 90:228-234(1994)	
	CCCB**	Takeshita, S, et al., Laboratory Investigation 74: 1061-1065 (1996)	
	CCCC**	Takeshita, S. et al., "Intramuscular Administration of Vascular Endothelial Growth Factor Induces Dose-Dependent Collateral Artery Augmentation in a Rabbit Model of Chronic Limb Ischemia." Circulation 1994 Nov;90(5 Pt 2):II228-34.	
	CCCD**	Terman, B. I. et al., Biochem. Biophys. Res. Commun. 187:1579 (1992)	
	CCCF**	Tischer, et al., J. Biol. Chem., 806:11947-11954 (1991)	
	CCCG**	Vitadello, M., et al., J. Clin. Invest. 90:626-630 (1992)	
	CCCH**	Weiss, M. et al., J. Clin. Invest., 97:591 (1996)	
	CCCI**	Witzenbichler et al. Chemotactic Properties of Angiopoietin-1 and -2, Ligands for the Endothelial-Specific Receptor Tyrosine Kinase Tie2. J. Biol. Chem 278:18514-18521, 1998.	
	CCCJ**	Wolff, J.A. et al, Science 247:1465-1468 (1990)	
	CCCK**	Yanagisawa-Miwa, et al., "Salvage of Infarcted Myocardium by Angiogenic Action of Basic Fibroblast Growth Factor" Science, 257:1401-1403 (1992).	
	CCCL**	Yanagisawa-Miwa, et al., Science, 257:1401-1403 (1992)	
	CCCM**	Zollman, F. et al., Circulation (in press)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--